---
document_datetime: 2025-04-03 10:33:08
document_pages: 3
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/copiktra-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: copiktra-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 1.6470998
conversion_datetime: 2025-12-23 00:38:36.232381
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Copiktra

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                              | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|----------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| IB/0007/G            | This was an application for a group of variations. | 10/08/2023                          |                                             | SmPC                             |           |

1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|                     | stability protocol                                                                                                                                                                                                                                                                                                                                                                          |            |            |                        |                                                                               |
|---------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|-------------------------------------------------------------------------------|
| IA/0008             | A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient                                                                                                                                                | 13/07/2023 | n/a        |                        |                                                                               |
| PSUSA/10939 /202209 | Periodic Safety Update EU Single assessment - duvelisib                                                                                                                                                                                                                                                                                                                                     | 14/04/2023 | n/a        |                        | PRAC Recommendation - maintenance                                             |
| PSUSA/10939 /202203 | Periodic Safety Update EU Single assessment - duvelisib                                                                                                                                                                                                                                                                                                                                     | 27/10/2022 | n/a        |                        | PRAC Recommendation - maintenance                                             |
| PSUSA/10939 /202109 | Periodic Safety Update EU Single assessment - duvelisib                                                                                                                                                                                                                                                                                                                                     | 07/04/2022 | n/a        |                        | PRAC Recommendation - maintenance                                             |
| II/0002             | Update of section 5.1 of the SmPC based on the final overall survival results from Study IPI-145-07, an interventinal Phase 3 Study of duvelisib (IPI-145) vs ofatumumab in patients with relapsed or refractory Chronic Lymphocytic leukemia/Small Lymphocytic Lymphoma. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data | 27/01/2022 | 03/02/2023 | SmPC                   | For more information, please refer to the Summary of Product Characteristics. |
| T/0001              | Transfer of Marketing Authorisation                                                                                                                                                                                                                                                                                                                                                         | 16/07/2021 | 20/08/2021 | SmPC, Labelling and PL |                                                                               |